Chemoprophylaxis trial designs in epidemics: insights from a systematic review of COVID-19 study registrations

ConclusionMany registered COVID-19 chemoprophylaxis efficacy trials were underpowered to detect clinically meaningful protection at epidemiologically informed attack rates. This, compounded with the time that has taken to organise these trials as compared to the rapid development of COVID-19 vaccines, has rendered these trials of marginal importance. International coordination mechanisms and collaboration is required. Supporting the design of feasible chemoprophylaxis trials, large enough to generate strong evidence, early on in an epidemic using adaptive platform trial designs will allow structured entry and exit of candidate agents  and rapid stand-up of trial infrastructure.Review protocol registrationOur protocol is registered athttps://www.osf.io/vp56f on May 20, 2020.
Source: Trials - Category: Research Source Type: clinical trials